PT  - JOURNAL ARTICLE
AU  - Wanlapakorn, Nasamon
AU  - Kanokudom, Sitthichai
AU  - Phowatthanasathian, Harit
AU  - Chansaenroj, Jira
AU  - Suntronwong, Nungruthai
AU  - Assawakosri, Suvichada
AU  - Yorsaeng, Ritthideach
AU  - Nilyanimit, Pornjarim
AU  - Vichaiwattana, Preeyaporn
AU  - Klinfueng, Sirapa
AU  - Thongmee, Thanunrat
AU  - Aeemjinda, Ratchadawan
AU  - Khanarat, Nongkanok
AU  - Srimuan, Donchida
AU  - Thatsanatorn, Thaksaporn
AU  - Sudhinaraset, Natthinee
AU  - Poovorawan, Yong
TI  - Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated followed by an mRNA vaccine in children aged 5 - 11 years
AID  - 10.1101/2022.11.07.22282028
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.11.07.22282028
4099  - http://medrxiv.org/content/early/2022/11/10/2022.11.07.22282028.short
4100  - http://medrxiv.org/content/early/2022/11/10/2022.11.07.22282028.full
AB  - Objective To compare the reactogenicity and immunogenicity between the two-dose mRNA COVID-19 vaccine regimen and one or two doses of inactivated vaccine followed by an mRNA vaccine regimen in healthy children between 5-11 years of age.Methods A prospective cohort study was performed at King Chulalongkorn Memorial Hospital in Thailand between March to June 2022. Healthy children between 5-11 years of age were enrolled and received the two-dose mRNA COVID-19 vaccine (BNT162b2) regimen or the inactivated (CoronaVac) vaccine followed by the BNT162b2 vaccine regimen. In addition, healthy children who received two doses of BBIBP-CorV between 1-3 months prior were enrolled to receive a heterologous BNT162b2 as a third dose (booster).Reactogenicity was assessed by a self-reported online questionnaire. Immunogenicity analysis was performed to determine binding and surrogate neutralizing antibodies to SARS-CoV-2 wild-type and Omicron variants.Results Overall, 166 eligible children were enrolled. Local and systemic AE which occurred within 7 days after vaccination were mild to moderate and well-tolerated. At one-month, post-two or post-three doses, children vaccinated with two-dose BNT162b2, CoronaVac/BNT162b2, and two-dose BBIBP-CorV followed by BNT162b2 elicited similar levels of anti-receptor-binding domain (RBD) IgG. However, the two-dose BNT162b2 and two-dose BBIBP-CorV followed by BNT162b2 groups elicited higher neutralizing activities against Omicron BA.2 variant than the CoronaVac/BNT162b2 group.Conclusion The heterologous, CoronaVac vaccine followed by the BNT162b2 vaccine, regimen elicited lower neutralizing activities against the emerging Omicron BA.2 variant than the two-dose mRNA regimen. A third dose (booster) mRNA vaccine should be prioritized for this group.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis trial was registered in the Thai Clinical Trials Registry (TCTR20220212001).Funding StatementThis research was financially supported by the Health Systems Research Institute (HSRI), National Research Council of Thailand (NRCT), the Center of Excellence in Clinical Virology, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, and partially supported by the Second Century Fund (C2F) of Sitthichai Kanokudom, Chulalongkorn University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Institutional Review Board (IRB) of the Faculty of Medicine of Chulalongkorn University (IRB 059/65) and was performed under the principles of the Declaration of Helsinki. This trial was registered in the Thai Clinical Trials Registry (TCTR20220212001). Written informed consent was obtained from the parents or the legal guardians of participants prior to enrollment. Written assent was obtained from children aged 7 years and above. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript